Cargando…

Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022

This real-world study explores the effect of coronavirus disease 2019 (COVID-19) inactivated vaccines on the prevention of asymptomatic or mild Delta or Omicron variant infections progressing to pneumonia. Association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cas...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Juan, Song, Rui, Yuan, Zheng, Xu, Zheng, Suo, Luodan, Wang, Qing, Li, Yuan, Gao, Yanlin, Li, Xiaomei, Chen, Xiaoyou, Wu, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413898/
https://www.ncbi.nlm.nih.gov/pubmed/36016103
http://dx.doi.org/10.3390/vaccines10081215
_version_ 1784775864056020992
author Li, Juan
Song, Rui
Yuan, Zheng
Xu, Zheng
Suo, Luodan
Wang, Qing
Li, Yuan
Gao, Yanlin
Li, Xiaomei
Chen, Xiaoyou
Wu, Jiang
author_facet Li, Juan
Song, Rui
Yuan, Zheng
Xu, Zheng
Suo, Luodan
Wang, Qing
Li, Yuan
Gao, Yanlin
Li, Xiaomei
Chen, Xiaoyou
Wu, Jiang
author_sort Li, Juan
collection PubMed
description This real-world study explores the effect of coronavirus disease 2019 (COVID-19) inactivated vaccines on the prevention of asymptomatic or mild Delta or Omicron variant infections progressing to pneumonia. Association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cases and vaccination was measured with a multivariable logistic regression, stratified by genotype and age groups. We recruited 265 cases (111 (41.9%) infected with Delta and 154 (58.1%) with Omicron variants). There were 22 asymptomatic infected individuals, 156 mild cases without pneumonia, and 87 moderate cases with pneumonia. There was a markedly increased risk of progression to pneumonia in Delta infected cases, unvaccinated, or partially vaccinated COVID-19 patients with diabetes and those aged ≥60 years. Patients who had completed booster doses of inactivated vaccines had a reduced risk of 81.6% (95% CI: 55.6–92.4%) in progressing to pneumonia over those who were unvaccinated or partially vaccinated. The risk of progressing to pneumonia was less reduced by 88.7% (95% CI: 56.6–97%) and 73.9% (95% CI: 1.4–93.1%) among Delta and Omicron-infected patients, and was reduced by 78.5% (95% CI: 45.3–91.6%) and 94.1% (95% CI: 21.5–99.6%) among patients aged <60 and ≥60 years, respectively. Our data indicated that a complete vaccination with a booster reduced the risk of asymptomatic or mild Delta or Omicron variant COVID-19 progressing to pneumonia and, thus, reduced the pressure of severe illness on medical resources.
format Online
Article
Text
id pubmed-9413898
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94138982022-08-27 Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 Li, Juan Song, Rui Yuan, Zheng Xu, Zheng Suo, Luodan Wang, Qing Li, Yuan Gao, Yanlin Li, Xiaomei Chen, Xiaoyou Wu, Jiang Vaccines (Basel) Article This real-world study explores the effect of coronavirus disease 2019 (COVID-19) inactivated vaccines on the prevention of asymptomatic or mild Delta or Omicron variant infections progressing to pneumonia. Association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cases and vaccination was measured with a multivariable logistic regression, stratified by genotype and age groups. We recruited 265 cases (111 (41.9%) infected with Delta and 154 (58.1%) with Omicron variants). There were 22 asymptomatic infected individuals, 156 mild cases without pneumonia, and 87 moderate cases with pneumonia. There was a markedly increased risk of progression to pneumonia in Delta infected cases, unvaccinated, or partially vaccinated COVID-19 patients with diabetes and those aged ≥60 years. Patients who had completed booster doses of inactivated vaccines had a reduced risk of 81.6% (95% CI: 55.6–92.4%) in progressing to pneumonia over those who were unvaccinated or partially vaccinated. The risk of progressing to pneumonia was less reduced by 88.7% (95% CI: 56.6–97%) and 73.9% (95% CI: 1.4–93.1%) among Delta and Omicron-infected patients, and was reduced by 78.5% (95% CI: 45.3–91.6%) and 94.1% (95% CI: 21.5–99.6%) among patients aged <60 and ≥60 years, respectively. Our data indicated that a complete vaccination with a booster reduced the risk of asymptomatic or mild Delta or Omicron variant COVID-19 progressing to pneumonia and, thus, reduced the pressure of severe illness on medical resources. MDPI 2022-07-29 /pmc/articles/PMC9413898/ /pubmed/36016103 http://dx.doi.org/10.3390/vaccines10081215 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Juan
Song, Rui
Yuan, Zheng
Xu, Zheng
Suo, Luodan
Wang, Qing
Li, Yuan
Gao, Yanlin
Li, Xiaomei
Chen, Xiaoyou
Wu, Jiang
Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022
title Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022
title_full Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022
title_fullStr Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022
title_full_unstemmed Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022
title_short Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022
title_sort protective effect of inactivated covid-19 vaccines against progression of sars-cov-2 omicron and delta variant infections to pneumonia in beijing, china, in 2022
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413898/
https://www.ncbi.nlm.nih.gov/pubmed/36016103
http://dx.doi.org/10.3390/vaccines10081215
work_keys_str_mv AT lijuan protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022
AT songrui protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022
AT yuanzheng protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022
AT xuzheng protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022
AT suoluodan protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022
AT wangqing protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022
AT liyuan protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022
AT gaoyanlin protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022
AT lixiaomei protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022
AT chenxiaoyou protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022
AT wujiang protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022